# PECATI (NCT04710628)

> Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: pretreated metastatic B3 thymoma and thymic carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04710628
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: MedSIR
- Conditions: Metastatic Thymic Carcinoma; Thymoma Type B3
- Interventions: Pembrolizumab; Lenvatinib 10 mg
- Enrollment: 43
- Primary outcome: Progression-free survival (PFS)

## Questions raised in the commentary

_Automated from all 14 indexed sources (Sep 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether PD-L1 predicts benefit from lenvatinib and pembrolizumab
- Whether randomized evidence can clarify the regimen’s benefit relative to other options
- How to manage treatment-related toxicity, including immune-related effects

Also discussed: lenvatinib dose intensity.

## Indexed commentary on PECATI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pecati-nct04710628

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04710628", "email": "<work email>"}; the inbox owner confirms by the emailed link.